March 7, 2024
Ono Pharmaceutical said on March 6 that it has concluded a worldwide license pact for NXI-101, a preclinical cancer drug candidate being developed by South Korean biotech firm NEX-I. The deal sees Ono obtaining the exclusive rights to globally develop...read more